FDA approve Arzerra (ofatumumab) as extended treatment for recurrent or progressive chronic lymphocytic leukemia

Genmab A/S has announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental Biologics License Application (sBLA) for the use of Arzerra® (ofatumumab) for extended… Source link